Clinical Trial Update: Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC) [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating Allo-ASC allogeneic mesenchymal stem cells for treatment of lateral epicondylitis (common extensor tendon injury).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lateral Epicondylitis

Drugs mentioned

• Allo-ASC (Allogeneic adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Lateral Epicondylitis | Phase 2 | Status: COMPLETED